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Edited by Felix WielandAbstract Insulin-like growth factors (IGFs) are important
mediators of growth and IGF-binding proteins (IGFBPs) 1–6
regulate IGF actions. As IGFBP C-terminal domains contribute
to high-aﬃnity IGF binding, we have deﬁned the binding site for
the C-domain of IGFBP-6 on IGF-II using NMR. This site lies
adjacent to and between the binding sites for the IGFBP N-
domain and IGF-I receptor (IGFIR), which have previously been
found on opposite sides of the IGF molecule. The C-domain is
therefore likely to interfere with IGF binding to the IGFIR,
providing a structural basis for the potent inhibitory eﬀects of
intact IGFBPs on IGF actions.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
The insulin-like growth factor (IGF) system is the major
control pathway of physiological growth in mammals [1]. IGF-
I and -II, the ligands in this system, are widely expressed and
play an important role in cell proliferation, diﬀerentiation and
survival. Dysregulation of the IGF system is associated with
many diseases such as cancer and diabetes [1–3], and there is
considerable interest in the development of IGF-based thera-
peutics for these diseases.
A family of six high-aﬃnity IGF-binding proteins (IGFBPs
1–6) regulates IGF activity [4–6]. IGFBPs inhibit IGF actions
by competing with the IGF-I receptor (IGFIR) for IGF
binding. IGFBPs can also enhance IGF actions in some situ-
ations by mechanisms that are incompletely understood. The
distinctive functional feature of IGFBP-6, the subject of the
present study, is its 20–100-fold higher binding aﬃnity for
IGF-II over IGF-I, resulting in IGFBP-6 being a relatively* Corresponding authors. Fax: +61-3-9496-3581 (L.A. Bach);
+61-3-9903-9655 (R.S. Norton).
E-mail addresses: l.bach@unimelb.edu.au (L.A. Bach),
ray.norton@wehi.edu.au (R.S. Norton).
Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like
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receptor
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growth of IGF-II-dependent tumors in vitro and in vivo [8,9],
which supports the view that inhibiting IGF actions may de-
crease cancer growth.
IGFBPs consist of three domains of approximately equal
size [4,6]. The N- and C-terminal domains of all IGFBPs each
share a high degree of sequence homology [10]. Isolated N-
and C-domains bind IGFs with lower aﬃnity than full-length
IGFBPs, implicating both of these in high-aﬃnity IGF binding
[6]. In contrast, there is little homology among the central L-
domains of IGFBPs and these are not thought to be directly
involved in IGF binding.
The IGF-I residues involved in binding to the N-terminal
domain of IGFBP-5 have been identiﬁed recently [11,12]. Al-
though the C-domains of IGFBPs are also important in high-
aﬃnity IGF binding [6,13,14], the IGF residues involved in this
binding interaction are unknown, precluding a complete un-
derstanding of the molecular mechanisms by which IGFBPs
modulate IGF actions. We therefore identiﬁed the C-domain
interactive surface of IGF-II by monitoring changes in the
NMR spectrum of 15N-labelled IGF-II following the addition
of unlabelled C-domain of IGFBP-6 (C-BP-6).2. Materials and methods
2.1. Samples
C-BP-6, expressed as a His6-tagged protein, was puriﬁed and char-
acterized as described previously [15]. Recombinant 15N-labelled IGF-
II was expressed, puriﬁed and characterized as described previously
[16,17].
2.2. NMR spectroscopy and C-domain interaction with IGF-II
To investigate the C-BP-6 binding site on IGF-II, 15N–1H HSQC
spectra of 0.6 mM 15N-labelled IGF-II in 10 mM sodium acetate and
0.05% (w/v) sodium azide at pH 3.5 were recorded in the presence and
absence of unlabelled C-BP-6 (0.3 mM). Spectra were recorded at 25
C on a Bruker DRX-600 using a triple-resonance probe equipped with
triple-axis gradients and an Avance 500 spectrometer equipped with a
cryoprobe. NMR data were processed in XWINNMR version 3.1
(Bruker Biospin) and analyzed using XEASY version 1.3 [18]. A pH of
3.5 was used for the direct observation of 15N–1H HSQC spectra of
15N-labelled IGF-II as these spectra show signiﬁcant line broadening
at higher pH [19] and this is the lowest pH at which binding still oc-
curs. In preliminary experiments, 15N–1H HSQC spectra of 0.3 mM
15N-labelled C-BP-6 in the presence of 0.3 mM unlabelled IGF-II were
recorded at pH 4.5, 4.0, 3.5 and 3.0. Maximal IGF-II-induced
broadening of peaks from C-BP-6 occurred at pH 4.0 but signiﬁcantblished by Elsevier B.V. All rights reserved.
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to resemble that of 15N-labelled C-BP-6 in the absence of IGF-II.
Therefore, pH 3.5 was selected for experiments investigating the C-BP-
6 binding site on IGF-II. IGF-II 15N–1H assignments were based on
those of Torres et al. [19]. The majority of cross-peaks from IGF-II
backbone amides showed some line broadening upon addition of un-
labelled C-BP-6.3. Results and discussion
3.1. The C-BP-6 binding site on IGF-II
NMR spectra of the IGFs show broader resonances than
would be predicted for proteins of their size [19], an eﬀect at-
tributed to oligomerization and/or conformational exchange.
Unambiguous assignments based on published chemical shifts
were made for all cross-peaks in the 15N–1H HSQC spectrum
of free IGF-II, with the exception of Leu8, Cys9, Arg30,
Arg40, Val43 and Glu67. IGF-II residues aﬀected by C-BP-6
binding were identiﬁed from changes in 15N–1H HSQC spectra
of 15N-labelled IGF-II upon addition of unlabelled C-BP-6.
The majority of backbone 15N–1H IGF-II resonances in the
structured regions of the molecule showed some line broad-
ening upon addition of unlabelled C-BP-6 (Fig. 1A). It is im-
portant to note, however, that numerous resonances in the
spectrum of IGF-II that arise from structured regions of the
protein (e.g., those around 8.8–9 ppm/124–126 ppm, including
Asp23, and 8.5 ppm/111 ppm, from Gly41, as well as several
less well-resolved peaks in Fig. 1A) are still clearly visible in
spectra of the complex, conﬁrming that the disappearance of
resonances in the complex is not simply a consequence of non-
speciﬁc line broadening of all resonances from structured re-
gions of IGF-II, which would leave only peaks from ﬂexible
regions of the ligand still visible. The largest decreases in
backbone cross-peak intensities were observed for IGF-II
residues Thr7, Gly10, Gly11, Glu12, Leu13, Val14, Asp15,
Thr16, Gln18, Cys21, Phe28, Ile42, Glu44, Cys46, Cys47,
Phe48, Arg49 and Cys51 (Fig. 1A). This is consistent with
these residues having a signiﬁcant exchange contribution to
their observed transverse relaxation rates as a result of inter-Fig. 1. (A) Comparison of 1H–15N HSQC of IGF-II in the presence (blue) an
side chain resonances in the 15N dimension are slightly diﬀerent in the two sp
from the top of the spectrum. Their chemical shifts in the 1H dimension (arou
peak intensity for free IGF-II decreased by >80% upon C-BP-6 addition (%
600 MHz). (B) Surfaces of IGF-II showing residues involved in N-domain bin
domains (magenta). Note that the 11 residues that contribute to the N-dom
rupted by the N-terminus; this arises because IGF-II contains an additional t
residues are disordered in the solution structure [19]. When IGF-II interacts
shift to expose the continuous N-domain binding surface identiﬁed in IGF-Imediate chemical exchange between the bound and free forms.
The exchange contribution is greatest for resonances that un-
dergo the largest changes in chemical shift upon ligand bind-
ing, which, in the absence of allosteric eﬀects, are usually those
residues located at the binding interface. Intermediate ex-
change occurs when the lifetime of the bound and free states is
approximately equal to the diﬀerences in chemical shift and/or
transverse relaxation rates between the free and ligand-bound
forms. As a consequence, the aﬀected resonances broaden
upon ligand addition and may even disappear [20]. Interme-
diate chemical exchange is commonly observed for proteins
with a Kd in the lM range. Our NMR observations are thus
consistent with the measured Kd for the C-BP-6/IGF-II inter-
action, determined by surface plasmon resonance (results not
shown).
As a consequence of the disappearance or severe broadening
of resonances from backbone amides of IGF-II upon complex
formation with C-BP-6, it was not practical to utilize the
method of saturation transfer [21,22] to map the binding in-
terface. In this method, magnetization is transferred from the
larger binding partner, in this case C-BP-6, to the ligand being
observed by NMR. Generally speaking, this approach pro-
vides a more precise picture of the binding surface than that
obtained by mapping chemical shift perturbations, which
usually identify a larger interaction surface than X-ray crys-
tallographic studies [23,24]. Thus, it should be borne in mind in
interpreting our results that the actual contact surface between
IGF-II and C-BP-6 is likely to be slightly smaller than inferred
from the observed spectral perturbations.
When mapped onto the solution structure of IGF-II solved
previously by us [19], the majority of residues aﬀected by C-
BP-6 binding are found on a continuous surface which forms a
putative C-BP-6 binding site (Fig. 1B). The binding site of
IGF-I to mini-IGFBP-5, which is part of the N-domain, is
already known [12]. IGF-I and IGF-II share 67% amino acid
identity and the residues within the N-domain binding site of
IGF-I are completely conserved in IGF-II. Moreover, of the
18 IGF-II residues aﬀected by incubation with the C-domain
of IGFBP-6, 15 are identical in IGF-I. As shown in Fig. 1B,d absence (red) of C-BP-6 (C-BP-6:IGF-II 0.5). The positions of some
ectra because diﬀerent sweep widths were used; these peaks are folded
nd 6.8–7.6 ppm) are not aﬀected. Residues labelled are those where the
decreases in intensity were averaged from spectra acquired at 500 and
ding (blue) and C-domain binding (red), and residues common to both
ain binding surface [12] appear to form a discontinuous surface inter-
hree residues at the N-terminus compared with IGF-I, and the ﬁrst ﬁve
with the N-domain of IGFBP-6, these N-terminal residues most likely
[12]. This ﬁgure was prepared using InsightII.
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surfaces of the IGF molecule. The N- and C-domains of full-
length IGFBPs are joined by a non-conserved, largely un-
structured linker region, which is not believed to be directly
involved in IGF binding. Based on our observations, the N-
and C-domains are brought close together upon IGF binding,
and it is likely that this ﬂexible linker region loops out from the
IGF molecule and does not directly interact with it.
The proposed C-BP-6 binding site on IGF-II explains site-
directed mutagenesis studies that have identiﬁed a number of
IGF residues important for IGFBP binding. These residues are
largely distinct from residues important for binding to the
IGFIR. In particular, mutation of IGF-II residues Glu6,
Phe26 and Phe48–Ser50 substantially decreases IGF-II binding
to IGFBPs [16,25,26] as does mutation in IGF-I of the
equivalents of Glu6, Thr7, Gln18 and Phe19 in IGF-II [27].
Mutation in IGF-I of the equivalents of Leu8, Gly10, Leu13,
Val20 and Phe28 in IGF-II reduces binding to IGFBP-1 sub-
stantially and to IGFBP-3 to a lesser extent [28]. From these
results, two patches of surface-exposed hydrophobic residues
that are involved in IGFBP binding were proposed. One patch,
including the IGF-II equivalents Glu6, Phe19 and Leu53, was
subsequently identiﬁed as the N-domain binding site, since the
IGF-I/mini-IGFBP-5 crystal structure showed that these side
chains were inserted deep into a cleft on mini-BP-5 [12]. The
other patch includes the IGF-II equivalents Gly10, Val14,
Phe28 and Val43. Extending this patch to include the adjacent
Cys9 and Cys48, which were not mutated because of their
disulﬁde link, results in a broader patch of residues that cor-
responds well to the C-domain binding site determined by
NMR in this study (Fig. 1B).
3.2. IGFBP inhibition of IGF binding to IGF receptors
The mitogenic eﬀects of IGFs are exerted mainly through
the IGFIR. A number of IGF residues are important for
binding to the IGFIR. In particular, mutation of Tyr27, Val43
or Tyr59 markedly reduces binding [29,30]. Mutation of Phe26Fig. 2. Schematic of the surface of IGF-II showing the binding site for
the IGFBP C-domain (red) lying between those for the IGFIR (IG-
FIR, cyan) and the IGFBP N-domain (blue). There is overlap between
residues identiﬁed as interacting with the C-domain and either the N-
domain or the IGFIR. Thr7, Glu12, Asp15, and Cys51 of IGF-II are
implicated in interactions with both the C- and N-domains; of these,
Glu12 and Asp15 are directly involved in binding to the N-domain [12]
and are shown in blue, while Thr7 and Cys51 are not in direct contact
and are shown in red. Both the C-domain and IGFIR are implicated in
interactions with Phe28, which is shown in cyan. Residues 1 and 67 are
labelled for orientation. This ﬁgure was prepared using InsightII.has a lesser eﬀect [29,30], although mutation of the equivalent
Phe in IGF-I had a more dramatic eﬀect [31]. Aromatic resi-
dues including Phe26, Tyr27 and Phe28 form a surface patch
on the opposite face of IGF-II to the mini-BP-5 binding site,
and it was suggested that this may explain the relative inability
of mini-BP-5 to completely inhibit IGFIR-dependent IGF
actions [11,12].
In contrast, the surface of IGF-II that binds to C-BP-6 lies
between the mini-BP-5 and IGFIR binding sites and overlaps
with the latter at Phe28 (Fig. 2). Steric hindrance by IGFBP C-
domains may therefore interfere with IGFIR binding. Alter-
natively, binding of IGFBP C-domains to this region may
prevent dissociation of the IGF b-strand from the body of the
molecule, a process that is important for binding of insulin to
its receptor and may therefore also be important for IGF
binding to the IGFIR [32]. The role of IGFBP C-domains in
complete inhibition of IGFIR actions can be explained struc-
turally by either of these alternatives.
IGF-II also binds with high aﬃnity to the IGF-II/mannose
6-phosphate receptor (IGF-II/M6PR), which is thought to
result predominantly in IGF-II clearance [5]. It appears that
the binding sites on IGF-II for C-domains of IGFBPs and
IGF-II/M6PR partially overlap, since mutagenesis of Phe48,
Arg49 and Ser50 of IGF-II to their equivalent insulin residues
(Thr, Ser, Ile, respectively) signiﬁcantly decreases binding both
to IGFBPs 1-6 [25] and to the IGF-II/M6PR [29]. In contrast,
mutation of Ala54 and Leu55 of IGF-II completely abrogates
IGF-II/M6PR binding [29], but has only modest eﬀects on
IGFBP binding [25]. Our NMR data are consistent with these
ﬁndings, as Phe48 and Arg49 were strongly aﬀected by C-BP-6
addition whereas Ala54 and Leu55 were not.
3.3. Conclusions
The C-domains of IGFBPs 1-6 are highly conserved. As a
consequence, the binding site identiﬁed on IGF-II for C-BP-6 is
likely to be largely the same for all IGFBPs. A number of
general conclusions can therefore be drawn about IGF:IGFBP
interactions as follows. The proximity of the IGF binding sites
for the C- and N-domains of IGFBPs is consistent with the view
that the L-domain acts as a ﬂexible linker region between the
two domains. Since C-BP-6 interacts with IGF-II residues that
are adjacent to and overlap the IGFIR binding site, it also
provides a structural basis for IGFBP inhibition of IGF binding
to the IGFIR. Since excess IGF activity is implicated in diseases
such as cancer, this knowledge also provides a framework for
the development of high aﬃnity therapeutic IGF antagonists.
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